Compare Dr. Reddys with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs VENUS REMEDIES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB VENUS REMEDIES DR. REDDYS LAB/
VENUS REMEDIES
 
P/E (TTM) x 33.6 -2.3 - View Chart
P/BV x 4.7 0.2 3,050.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 DR. REDDYS LAB   VENUS REMEDIES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
VENUS REMEDIES
Mar-18
DR. REDDYS LAB/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs2,875126 2,283.6%   
Low Rs1,88861 3,090.0%   
Sales per share (Unadj.) Rs930.2301.8 308.2%  
Earnings per share (Unadj.) Rs117.4-24.9 -472.1%  
Cash flow per share (Unadj.) Rs185.82.5 7,300.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.4293.3 287.9%  
Shares outstanding (eoy) m166.0712.34 1,345.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.60.3 826.3%   
Avg P/E ratio x20.3-3.8 -539.5%  
P/CF ratio (eoy) x12.836.7 34.9%  
Price / Book Value ratio x2.80.3 884.6%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4961,154 34,278.0%   
No. of employees `00022.00.9 2,374.7%   
Total wages/salary Rs m33,562393 8,537.8%   
Avg. sales/employee Rs Th7,032.84,026.1 174.7%   
Avg. wages/employee Rs Th1,527.9425.0 359.5%   
Avg. net profit/employee Rs Th887.7-331.8 -267.6%   
INCOME DATA
Net Sales Rs m154,4823,724 4,148.2%  
Other income Rs m3,37523 15,000.0%   
Total revenues Rs m157,8573,747 4,213.3%   
Gross profit Rs m31,782395 8,050.2%  
Depreciation Rs m11,348338 3,354.4%   
Interest Rs m889354 250.9%   
Profit before tax Rs m22,920-275 -8,325.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,85832 12,208.9%   
Profit after tax Rs m19,500-307 -6,353.9%  
Gross profit margin %20.610.6 194.1%  
Effective tax rate %16.8-11.5 -146.6%   
Net profit margin %12.6-8.2 -153.2%  
BALANCE SHEET DATA
Current assets Rs m111,1012,638 4,212.1%   
Current liabilities Rs m58,9732,305 2,558.9%   
Net working cap to sales %33.78.9 377.3%  
Current ratio x1.91.1 164.6%  
Inventory Days Days79135 58.6%  
Debtors Days Days9446 203.3%  
Net fixed assets Rs m101,2454,871 2,078.6%   
Share capital Rs m830123 672.6%   
"Free" reserves Rs m139,4063,496 3,988.0%   
Net worth Rs m140,2363,619 3,874.9%   
Long term debt Rs m22,0001,374 1,600.7%   
Total assets Rs m224,6567,509 2,992.0%  
Interest coverage x26.80.2 12,011.1%   
Debt to equity ratio x0.20.4 41.3%  
Sales to assets ratio x0.70.5 138.6%   
Return on assets %9.10.6 1,437.6%  
Return on equity %13.9-8.5 -164.0%  
Return on capital %14.91.6 944.7%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m88,6730-   
Fx outflow Rs m19,104517 3,698.7%   
Net fx Rs m69,569-517 -13,469.3%   
CASH FLOW
From Operations Rs m28,704514 5,580.1%  
From Investments Rs m-7,727-123 6,277.0%  
From Financial Activity Rs m-21,326-387 5,509.2%  
Net Cashflow Rs m-3144 -7,476.2%  

Share Holding

Indian Promoters % 25.5 32.9 77.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 0.2 3,000.0%  
FIIs % 35.3 0.6 6,086.2%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 66.4 23.0%  
Shareholders   75,885 20,121 377.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  CIPLA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; IndusInd Bank & Bajaj Finance Top Losers(12:30 pm)

Share markets in India have erased early gains and are presently trading on a volatile note, fluctuating between gains and losses.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 4, 2020 01:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS